CM
APGN

Crestline Management’s Apexigen, Inc. Common Stock APGN Stock Holding History

Crestline Management’s Portfolio APGN Stock Details APGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-40,961
Closed -$413K – 322
2022
Q1 		$413K Hold
40,961
– – 0.05% 196
2021
Q4 		$410K Hold
40,961
– – 0.03% 183
2021
Q3 		$408K Hold
40,961
– – 0.04% 176
2021
Q2 		$406K Buy
+40,961
New +$406K 0.04% 141

Other funds holding APGN

MSU
Mizuho Securities USA New York $4.24B AUM 22.54% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return

Crestline Management's APGN Position: Q2 2022 in Review

Crestline Management sold out of Apexigen, Inc. Common Stock (APGN) in Q2 2022, closing a stake of 40,961 shares — an estimated $413K sold.

Crestline Management first reported a position in APGN in Q2 2021 and held it in 4 quarters. The position peaked at $413K in Q1 2022. 27 funds tracked by Wall St. Rank hold APGN as of Q2 2022.

  • Crestline Management reported no remaining Apexigen, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Crestline Management sold 40,961 Apexigen, Inc. Common Stock shares in Q2 2022, an estimated $413K.
  • Crestline Management first reported a position in Apexigen, Inc. Common Stock in Q2 2021 and held it in 4 quarters.
  • Crestline Management's Apexigen, Inc. Common Stock position peaked at $413K in Q1 2022.
  • 27 funds tracked by Wall St. Rank held Apexigen, Inc. Common Stock as of Q2 2022.

Based on Crestline Management's 13F filing for Q2 2022, filed 12 Aug 2022.